AzTrials
AzTrials

Premature BirthNCT02189265

Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands

An observational study of Premature Birth and Perinatal Mortality, run by University of Edinburgh at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate whether there has been a change in perinatal outcomes following the phased smoking ban introduction (January 2004 for workplaces; July 2008 for bars and restaurants) workplaces in the Netherlands. Read more about this study

Who is it for?
Ages Up to 1 weekHealthy volunteers can take part
What is being tested?
Smoke-free legislation
How many people
2,069,695 participants
Where
2 sitesin 2 countries
Study dates
Jan 2000to Jul 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 1 week
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than stillbirths and congenital anomalies.

Who may be able to join

  • Singleton birth occurring in the Netherlands between January 1st, 2000 and December 31st, 2011
  • Liveborn (for all outcomes other than stillbirth and congenital anomalies)

Who cannot join

  • No chromosomal anomalies

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

Netherlands1 site
  • Academic Medical Centre

    Amsterdam, North Holland

Other trials in Netherlands

United Kingdom1 site
  • Centre for Population Health Sciences, The University of Edinburgh

    Edinburgh, Midlothian, EH8 9AG

Other trials in United Kingdom

About this study

The purpose of this study is to investigate whether there has been a change in perinatal outcomes following the phased smoking ban introduction (January 2004 for workplaces; July 2008 for bars and restaurants) workplaces in the Netherlands.

Read the detailed description

Primary research questions

  1. Is the phased introduction of smoke-free legislation in The Netherlands associated with reductions in adverse perinatal outcomes (e.g. perinatal mortality, preterm birth, small for gestational age)?
  2. How do these associations compare with those described for other European countries in comparable studies (i.e. Belgium (Cox 2013), England (Been et al under review), Scotland (Mackay 2012))?

Study design Retrospective cohort study (using prospective routinely collected health care data)

Study population All singleton births in the Netherlands between January 1st 2000 and December 31st 2011.

Intervention The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.

Inclusion and exclusion criteria We will include all registered singleton births in the Netherlands occurring between January 1st, 2000 and December 31st, 2011. This is the maximum time period surrounding the ban's introduction for which the required birth data are available through the data source. Multiple pregnancies, neonates with chromosomal anomalies, pregnancies with unknown gestational age, pregnancies that ended before 24 weeks and pregnancies resulting in the birth of a child weighing less than 500 grams will be excluded.

Outcome

The primary outcomes are:

  • Perinatal mortality (stillbirth + early neonatal mortality, i.e. within the first 7 days of life)
  • Preterm birth (live birth with gestational age <37+0 weeks)
  • Small for gestational age (SGA; live birth with birth weight below 10th centile; The Dutch PRN reference curves for birth weight by gestational age according to parity, sex and ethnic background will be used)

To assess whether smoke-free legislation had a selective impact on certain subgroups of outcomes we furthermore identified a number of secondary outcomes:

  • Stillbirth (born dead from 24+0 weeks of gestation)
  • Early neonatal mortality (live birth and death within first 7 days)
  • Very preterm birth (live birth with gestational age <32+0 weeks)
  • Low birth weight (live birth with birth weight <2500 grams)
  • Very low birth weight (live birth with birth weight <1500 grams)
  • Very small for gestational age (live birth with birth weight below percentile 2.3rd centile)
  • Major congenital anomalies (based on reported associations with antenatal smoke exposure (Hackshaw 2011)).

Data sources Individual level health care data will be extracted from The Netherlands Perinatal Registry (PRN). Linked midwifery, obstetric, and neonatal data are available from 2000 to 2011 (including 2011).

Data extraction and handling All relevant variables regarding our outcomes, as well as relevant potential confounders will be extracted from the database.

Sample size Power calculation for interrupted time series modelling is complicated given the complexity of the analysis. Similar previous studies have demonstrated statistically significant and clinically relevant effects of smoke-free legislation on preterm birth (Cox 2013; Mackay 2012; Page 2012), low birth weight (Mackay 2012), SGA (Mackay 2012; Kabir 2013), and perinatal mortality (Mackay et al. and Been et al. both under review). Given the larger population size of the Netherlands as opposed to the regions in which these studies were carried out (except for Been et al. under review), we expect our study to have sufficient power to detect similar effect sizes, should these be present.

Statistical analysis Incidences for each outcome will be presented graphically for each time period to facilitate visualisation of temporal fluctuations and trends in changes of incidence levels. To facilitate timing of the events, date of delivery and expected term date are required for each pregnancy. Data will be presented as outlined in different Tables. Interrupted time series analyses with adjustment for potential confounders will be performed to assess the associations between implementation of smoke-free legislation and primary and secondary outcome measures. Individual-level analysis will be performed using logistic regression analysis. The models will account for the underlying temporal trend in incidence, and will allow for a sudden change in incidence ('step change') following the introduction of the smoking bans. We will test and adjust for any non-linearity in the underlying time trends, and seasonality will be accounted as appropriate.

Sensitivity analyses (primary outcomes only) In recent years, gestational age is usually estimated based on early ultrasonography findings, which is more reliable than estimation based on the last menstrual period. Although the method of ascertainment is not recorded in PRN, there is an item indicating 'certainty' of the gestational age, which is positive in about 93% of records. For the primary outcomes preterm birth and SGA we will perform a sensitivity analysis including only cases in whom gestational age estimation is considered reliable according to this item.

Recent perinatal management changes have been implemented in The Netherlands resulting in increased active management of babies born at the edge of viability (i.e. 23-24 weeks gestation) (NVOG 2010). This has resulted in increased survival at this gestational age as well as altered management of 25-26 week infants, which likely affects the number of babies born preterm (although this effect is expected to be small given the small percentage of all preterm babies being born at this stage), as well as mortality indicators. For the primary outcomes preterm birth and perinatal mortality we will therefore perform a sensitivity analysis excluding babies born before 26 completed weeks of gestation.

Smoking during pregnancy is known to be underreported in the PRN database. Definitions between different caregivers differ; (any) smoking and heavy smoking (>20 cigarettes daily). We will consider performing subgroup analyses of the impact of smoke-free legislation on the primary outcomes according to maternal smoking status during pregnancy.

In a sensitivity analysis we will investigate whether smoke-free legislation has any differential impact on spontaneous preterm birth versus medically indicated preterm birth.

All analyses will be performed using Stata 13.0.

Being tested
Smoke-free legislation
Keywords
Live birth [MeSH], Infant [MeSH], Infant, newborn [MeSH], Second-hand smoke, Tobacco smoke pollution [MeSH], Smoke-free, Smoke-free policy [MeSH]
Medical subject headings
Premature Birth, Perinatal Death, Stillbirth, Infant Death, Sudden Infant Death

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Smoke-free legislationOther

    The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.

Study groups in NCT02189265
Study groupRoleWhat they receive
Full cohortAll singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
Receives: Other: Smoke-free legislation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Perinatal mortality

    stillbirth (i.e. intrauterine death from 24+0 weeks gestation) or early neonatal mortality (i.e. death within the first 7 days postnatally)

    Measured: from 24+0 weeks gestation (for stillbirth); up to 7 days postnatally (for early neonatal mortality)

  2. Preterm birth

    live birth with gestational age >= 24+0 weeks and <37+0 weeks

    Measured: gestational age >= 24+0 weeks and <37+0 weeks

  3. Small for gestational age

    live birth at gestational age >= 24+0 weeks with birth weight below 10th centile

    Measured: gestational age >= 24+0 weeks

Secondary outcomes (7)
  1. Stillbirth

    born dead from 24+0 weeks of gestation

    Measured: gestational age >= 24+0 weeks

  2. Early neonatal mortality

    death within first 7 days after live birth at gestational age >= 24+0 weeks

    Measured: up to 7 days postnatally after live birth at gestational age >= 24+0 weeks

  3. Very preterm birth

    live birth with gestational age >= 24+0 weeks and <32+0 weeks

    Measured: gestational age >= 24+0 weeks and <32+0 weeks

  4. Low birth weight

    live birth at gestational age >= 24+0 weeks with birth weight <2500 grams

    Measured: gestational age >= 24+0 weeks

  5. Very low birth weight

    live birth at gestational age >= 24+0 weeks with birth weight <1500 grams

    Measured: gestational age >= 24+0 weeks

  6. Very small for gestational age

    live birth at gestational age >= 24+0 weeks with birth weight below 2.3rd centile

    Measured: gestational age >= 24+0 weeks

  7. Major congenital anomalies

    birth at >= 24+0 weeks of gestation with a major birth defect (birth defects known to be influenced by antenatal smoke exposure based on recent systematic review (Hackshaw 2011))

    Measured: gestational age >= 24+0 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2014 (estimated)
  2. Study startJan 2000
  3. Primary completionDec 2011
  4. Study completionJul 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Retrospective
Enrolment
2,069,695 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02189265
Sponsor's protocol ID
TRF NR-0166-1.3
Status last verified
Jul 2014
First submitted
3 Jul 2014
Last updated
14 Jul 2014
Results posted
No
Data monitoring committee
No

Publications

  • Cox B, Martens E, Nemery B, Vangronsveld J, Nawrot TS. Impact of a stepwise introduction of smoke-free legislation on the rate of preterm births: analysis of routinely collected birth data. BMJ. 2013 Feb 14;346:f441. doi: 10.1136/bmj.f441.

    PubMed 23412829
  • Mackay DF, Nelson SM, Haw SJ, Pell JP. Impact of Scotland's smoke-free legislation on pregnancy complications: retrospective cohort study. PLoS Med. 2012;9(3):e1001175. doi: 10.1371/journal.pmed.1001175. Epub 2012 Mar 6.

    PubMed 22412353
  • Page RL 2nd, Slejko JF, Libby AM. A citywide smoking ban reduced maternal smoking and risk for preterm births: a Colorado natural experiment. J Womens Health (Larchmt). 2012 Jun;21(6):621-7. doi: 10.1089/jwh.2011.3305. Epub 2012 Mar 8.

    PubMed 22401497
  • Kabir Z, Daly S, Clarke V, Keogan S, Clancy L. Smoking ban and small-for-gestational age births in Ireland. PLoS One. 2013;8(3):e57441. doi: 10.1371/journal.pone.0057441. Epub 2013 Mar 26.

    PubMed 23555561
  • Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011 Sep-Oct;17(5):589-604. doi: 10.1093/humupd/dmr022. Epub 2011 Jul 11.

    PubMed 21747128
  • de Laat MW, Wiegerinck MM, Walther FJ, Boluyt N, Mol BW, van der Post JA, van Lith JM, Offringa M; Nederlandse Vereniging voor Kindergeneeskunde; Nederlandse Vereniging voor Obstetrie en Gynaecologie. [Practice guideline 'Perinatal management of extremely preterm delivery']. Ned Tijdschr Geneeskd. 2010;154:A2701. Dutch.

    PubMed 21429260
  • Peelen MJ, Sheikh A, Kok M, Hajenius P, Zimmermann LJ, Kramer BW, Hukkelhoven CW, Reiss IK, Mol BW, Been JV. [Tobacco control policies and perinatal health]. Ned Tijdschr Geneeskd. 2017;161:D563. Dutch.

    PubMed 28120730
  • Peelen MJ, Sheikh A, Kok M, Hajenius P, Zimmermann LJ, Kramer BW, Hukkelhoven CW, Reiss IK, Mol BW, Been JV. Tobacco control policies and perinatal health: a national quasi-experimental study. Sci Rep. 2016 Apr 22;6:23907. doi: 10.1038/srep23907.

    PubMed 27103591

Questions about this trial

What is this clinical trial studying?

An observational study of Premature Birth and Perinatal Mortality, run by University of Edinburgh at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Perinatal mortality (time frame: from 24+0 weeks gestation (for stillbirth); up to 7 days postnatally (for early neonatal mortality)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02189265, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in